search
Back to results

Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
exenatide
exenatide
placebo
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring diabetes, exenatide, LY2148568, Byetta, Lilly, Amylin

Eligibility Criteria

20 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosed with type 2 diabetes.
  • Has been treated by sulfonylurea (SU) alone, SU and biguanide, or SU and thiazolidinedione for at least 90 days prior to study start. In a patient receiving SU alone, the dose must be within the dose range from maximum maintenance dose to maximum approved dose. The patients with concomitant use of alpha glucosidase inhibitors (acarbose, voglibose or miglitol) or meglitinide derivatives (mitiglinide or nateglinide) can be included in this study, but these drugs must be discontinued at study start.
  • Have HbA1c 7.0% to 10% at study start.
  • Have a body weight >=50 kg.

Exclusion Criteria:

  • Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
  • Have participated in this study previously or any other study using exenatide or glucagon-like peptide-1 (GLP-1) analogs within the last 90 days.
  • Have been treated with any exogenous insulin within 90 days before study start.
  • Have been continuously treated with any drug that directly affects gastrointestinal motility for more than a total of 21 days in the 90 days prior to study start.
  • The combination therapy of sulfonylurea, biguanide and thiazolidinedione is not allowed.

Sites / Locations

  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

1

2

3

Arm Description

Outcomes

Primary Outcome Measures

Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24
Change in HbA1c from baseline following 24 weeks of treatment (i.e., HbA1c at week 24 minus HbA1c at week 0)

Secondary Outcome Measures

Percentage of Patients Achieving HbA1c < 7.0%
Percentage of subjects whose HbA1c was >=7.0% at baseline who achieved an HbA1c < 7.0% at endpoint (i.e., number of eligible subjects who achieved HbA1c < 7.0% divided by total number of eligible subjects times 100)
Percentage of Patients Achieving HbA1c < 6.5%
Percentage of subjects whose HbA1c was >=6.5% at baseline who achieved an HbA1c < 6.5% at endpoint (i.e., number of eligible subjects who achieved HbA1c < 6.5% divided by total number of eligible subjects times 100)
Change in Fasting Blood Glucose
Change in fasting blood glucose from baseline to endpoint (i.e., fasting blood glucose at week 24 minus fasting blood glucose at week 0)
Change in Body Weight
Change in body weight form baseline to endpoint (i.e., body weight at week 24 minus body weight at week 0)
Change in Total Cholesterol
Change in total cholesterol from baseline to endpoint (i.e., total cholesterol at week 24 minus total cholesterol at week 0)
Change in Low Density Lipoprotein Cholesterol (LDL-C)
Change in LDL-C from baseline to endpoint (i.e., LDL-C at week 24 minus LDL-C at week 0)
Change in High Density Lipoprotein Cholesterol (HDL-C)
Change in HDL-C from baseline to endpoint (i.e., HDL-C at week 24 minus HDL-C at week 0)
Change in Triglycerides
Change in triglycerides from baseline to endpoint (i.e., triglycerides at week 24 minus triglycerides at week 0)
Change in Waist Size
Change in waist size from baseline to endpoint (i.e., waist size at week 24 minus waist size at week 0)
Change in Waist-to-hip Ratio
Change in waist-to-hip ratio from baseline to endpoint (i.e., waist-to-hip ratio at week 24 minus waist-to-hip ratio at week 0). Waist-to-hip ratio is waist circumference divided by hip circumference.
7 Point Self-monitored Blood Glucose (SMBG) Profiles at Baseline and Week 24
Self-monitored blood glucose at 7 different time points during the day (glucose measurements before and 2 hours after the start of the morning, midday, and evening meals, and at bedtime).
Change in Homeostasis Model Assessment - Beta Cell Function (HOMA-B)
Change in HOMA-B from baseline to endpoint (i.e., HOMA-B at week 24 minus HOMA-B at week 0). HOMA-B is a measurement of beta cell function.
Change in Homeostasis Model Assessment - Insulin Resistance (HOMA-R)
Change in HOMA-R from baseline to endpoint (i.e., HOMA-R at week 24 minus HOMA-R at week 0). HOMA-R is a measurement of insulin resistance.
Change in Serum Insulin
Change in serum insulin from baseline to endpoint (i.e., serum insulin at week 24 minus serum insulin at week 0)
Change in C-peptide
Change in C-peptide from baseline to endpoint (i.e., C-peptide at week 24 minus C-peptide at week 0)
Change in 1,5-anhydroglucitol
Change in 1,5-anhydroglucitol from baseline to endpoint (i.e., 1,5-anhydroglucitol at week 24 minus 1,5-anhydroglucitol at week 0)

Full Information

First Posted
December 18, 2007
Last Updated
March 20, 2015
Sponsor
AstraZeneca
Collaborators
Eli Lilly and Company
search

1. Study Identification

Unique Protocol Identification Number
NCT00577824
Brief Title
Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)
Official Title
Efficacy and Safety of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled
Study Type
Interventional

2. Study Status

Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
January 2008 (undefined)
Primary Completion Date
November 2008 (Actual)
Study Completion Date
November 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
Collaborators
Eli Lilly and Company

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This long term, placebo-controlled trial is intended to assess the efficacy and safety of exenatide, dosed twice a day, in Japanese patients with Type 2 Diabetes who are treated with oral antidiabetic(s) but not well controlled.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
diabetes, exenatide, LY2148568, Byetta, Lilly, Amylin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
181 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Title
2
Arm Type
Experimental
Arm Title
3
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
exenatide
Other Intervention Name(s)
LY2148568, Byetta
Intervention Description
subcutaneous injection, 5mcg, twice a day
Intervention Type
Drug
Intervention Name(s)
exenatide
Other Intervention Name(s)
LY2148568, Byetta
Intervention Description
subcutaneous injection, 10mcg, twice a day
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day
Primary Outcome Measure Information:
Title
Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24
Description
Change in HbA1c from baseline following 24 weeks of treatment (i.e., HbA1c at week 24 minus HbA1c at week 0)
Time Frame
baseline, 24 weeks
Secondary Outcome Measure Information:
Title
Percentage of Patients Achieving HbA1c < 7.0%
Description
Percentage of subjects whose HbA1c was >=7.0% at baseline who achieved an HbA1c < 7.0% at endpoint (i.e., number of eligible subjects who achieved HbA1c < 7.0% divided by total number of eligible subjects times 100)
Time Frame
24 weeks
Title
Percentage of Patients Achieving HbA1c < 6.5%
Description
Percentage of subjects whose HbA1c was >=6.5% at baseline who achieved an HbA1c < 6.5% at endpoint (i.e., number of eligible subjects who achieved HbA1c < 6.5% divided by total number of eligible subjects times 100)
Time Frame
24 weeks
Title
Change in Fasting Blood Glucose
Description
Change in fasting blood glucose from baseline to endpoint (i.e., fasting blood glucose at week 24 minus fasting blood glucose at week 0)
Time Frame
baseline, week 24
Title
Change in Body Weight
Description
Change in body weight form baseline to endpoint (i.e., body weight at week 24 minus body weight at week 0)
Time Frame
baseline, week 24
Title
Change in Total Cholesterol
Description
Change in total cholesterol from baseline to endpoint (i.e., total cholesterol at week 24 minus total cholesterol at week 0)
Time Frame
baseline, week 24
Title
Change in Low Density Lipoprotein Cholesterol (LDL-C)
Description
Change in LDL-C from baseline to endpoint (i.e., LDL-C at week 24 minus LDL-C at week 0)
Time Frame
baseline, week 24
Title
Change in High Density Lipoprotein Cholesterol (HDL-C)
Description
Change in HDL-C from baseline to endpoint (i.e., HDL-C at week 24 minus HDL-C at week 0)
Time Frame
baseline, week 24
Title
Change in Triglycerides
Description
Change in triglycerides from baseline to endpoint (i.e., triglycerides at week 24 minus triglycerides at week 0)
Time Frame
baseline, week 24
Title
Change in Waist Size
Description
Change in waist size from baseline to endpoint (i.e., waist size at week 24 minus waist size at week 0)
Time Frame
baseline, week 24
Title
Change in Waist-to-hip Ratio
Description
Change in waist-to-hip ratio from baseline to endpoint (i.e., waist-to-hip ratio at week 24 minus waist-to-hip ratio at week 0). Waist-to-hip ratio is waist circumference divided by hip circumference.
Time Frame
baseline, week 24
Title
7 Point Self-monitored Blood Glucose (SMBG) Profiles at Baseline and Week 24
Description
Self-monitored blood glucose at 7 different time points during the day (glucose measurements before and 2 hours after the start of the morning, midday, and evening meals, and at bedtime).
Time Frame
baseline, week 24
Title
Change in Homeostasis Model Assessment - Beta Cell Function (HOMA-B)
Description
Change in HOMA-B from baseline to endpoint (i.e., HOMA-B at week 24 minus HOMA-B at week 0). HOMA-B is a measurement of beta cell function.
Time Frame
baseline, week 24
Title
Change in Homeostasis Model Assessment - Insulin Resistance (HOMA-R)
Description
Change in HOMA-R from baseline to endpoint (i.e., HOMA-R at week 24 minus HOMA-R at week 0). HOMA-R is a measurement of insulin resistance.
Time Frame
baseline, week 24
Title
Change in Serum Insulin
Description
Change in serum insulin from baseline to endpoint (i.e., serum insulin at week 24 minus serum insulin at week 0)
Time Frame
baseline, week 24
Title
Change in C-peptide
Description
Change in C-peptide from baseline to endpoint (i.e., C-peptide at week 24 minus C-peptide at week 0)
Time Frame
baseline, week 24
Title
Change in 1,5-anhydroglucitol
Description
Change in 1,5-anhydroglucitol from baseline to endpoint (i.e., 1,5-anhydroglucitol at week 24 minus 1,5-anhydroglucitol at week 0)
Time Frame
baseline, week 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosed with type 2 diabetes. Has been treated by sulfonylurea (SU) alone, SU and biguanide, or SU and thiazolidinedione for at least 90 days prior to study start. In a patient receiving SU alone, the dose must be within the dose range from maximum maintenance dose to maximum approved dose. The patients with concomitant use of alpha glucosidase inhibitors (acarbose, voglibose or miglitol) or meglitinide derivatives (mitiglinide or nateglinide) can be included in this study, but these drugs must be discontinued at study start. Have HbA1c 7.0% to 10% at study start. Have a body weight >=50 kg. Exclusion Criteria: Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. Have participated in this study previously or any other study using exenatide or glucagon-like peptide-1 (GLP-1) analogs within the last 90 days. Have been treated with any exogenous insulin within 90 days before study start. Have been continuously treated with any drug that directly affects gastrointestinal motility for more than a total of 21 days in the 90 days prior to study start. The combination therapy of sulfonylurea, biguanide and thiazolidinedione is not allowed.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chief Medical Officer, MD
Organizational Affiliation
Eli Lilly and Company
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Chiba
Country
Japan
Facility Name
Research Site
City
Fukuoka
Country
Japan
Facility Name
Research Site
City
Fukushima
Country
Japan
Facility Name
Research Site
City
Hyogo
Country
Japan
Facility Name
Research Site
City
Ibaragi
Country
Japan
Facility Name
Research Site
City
Kanagawa
Country
Japan
Facility Name
Research Site
City
Kumamoto
Country
Japan
Facility Name
Research Site
City
Kyoto
Country
Japan
Facility Name
Research Site
City
Nagano
Country
Japan
Facility Name
Research Site
City
Oita
Country
Japan
Facility Name
Research Site
City
Osaka
Country
Japan
Facility Name
Research Site
City
Tokyo
Country
Japan

12. IPD Sharing Statement

Citations:
PubMed Identifier
24843486
Citation
Kadowaki T, Namba M, Imaoka T, Yamamura A, Goto W, Boardman MK, Sowa H. Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. J Diabetes Investig. 2011 Jun 5;2(3):210-7. doi: 10.1111/j.2040-1124.2010.00084.x.
Results Reference
result
PubMed Identifier
24843529
Citation
Inagaki N, Ueki K, Yamamura A, Saito H, Imaoka T. Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes. J Diabetes Investig. 2011 Nov 30;2(6):448-56. doi: 10.1111/j.2040-1124.2011.00137.x.
Results Reference
result
PubMed Identifier
22913891
Citation
Pencek R, Blickensderfer A, Li Y, Brunell SC, Anderson PW. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med. 2012 Jul;124(4):21-32. doi: 10.3810/pgm.2012.07.2567.
Results Reference
derived

Learn more about this trial

Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)

We'll reach out to this number within 24 hrs